Ava Fertility Bracelet: FDA-Cleared Wearable for Fertile Window Detection

A clinical study of 237 women found that a wearable bracelet tracking five physiological signals could detect the fertile window with 90% accuracy. That bracelet became a commercial product, and the science behind it remains the strongest published validation for any consumer fertility wearable.

Presented By Our Partners

The fertile window, the roughly six days per cycle when conception is possible, has been notoriously difficult to identify in real time. Traditional methods rely on indirect signals: cervical mucus observation, urinary luteinizing hormone (LH) surges, or basal body temperature (BBT) charting that confirms ovulation only after it has already occurred. In 2019, a prospective longitudinal study published in the Journal of Medical Internet Research by Goodale et al. demonstrated a different approach. By equipping 237 conception-seeking women with a wrist-worn sensor that simultaneously tracked skin temperature, heart rate, respiratory rate, heart rate variability, and skin perfusion during sleep, the research team developed a machine learning algorithm that detected the fertile window with 90% accuracy (95% CI 0.89 to 0.92). The study showed that multiple physiological parameters shift concurrently across the menstrual cycle and that a multi-sensor approach could identify the fertile window in real time, not retrospectively. The device used in that study was the Ava Fertility Bracelet.

What Is the Ava Fertility Bracelet?

The Ava Fertility Bracelet is a wrist-worn wearable designed to be worn during sleep. It uses multiple onboard sensors to measure five physiological parameters: skin temperature, resting pulse rate, breathing rate, heart rate variability (HRV ratio), and skin perfusion. The device syncs to a companion smartphone app each morning, where its algorithm analyzes the overnight data to identify the user’s position in her menstrual cycle and predict her fertile window.

Unlike BBT-only methods that confirm ovulation retrospectively, Ava’s multi-parameter approach aims to detect the opening of the fertile window in real time, identifying an average of 5.3 fertile days per cycle according to the company’s published data. The bracelet charges via USB and lasts approximately one year on its rechargeable battery before replacement. The companion app provides daily fertility status, cycle tracking, projected fertile days for upcoming cycles, and pregnancy mode for users who conceive.

Ava holds FDA clearance for fertility tracking, distinguishing it from general wellness wearables that cannot make fertility-related claims. The device is HSA and FSA eligible. Priced at approximately $299 with no subscription required for core features, Ava is positioned as a premium fertility wearable for women who are actively trying to conceive.

The Science Behind Multi-Parameter Fertility Detection

The menstrual cycle produces measurable shifts across multiple physiological systems, not just body temperature. These shifts are driven by the hormonal cascade that governs follicular development, ovulation, and luteal phase progesterone production. Understanding why Ava tracks five parameters simultaneously requires understanding what each one reveals about cycle phase.

Skin temperature rises during the luteal phase due to progesterone’s thermogenic effect on the hypothalamic thermoregulatory center. This is the same signal that traditional BBT charting detects, but Ava measures it continuously during sleep through a wrist-worn sensor rather than requiring a single-point oral measurement at a consistent wake time. Resting pulse rate increases during the luteal phase, reflecting progesterone’s vasodilatory effects and increased cardiac output. Breathing rate similarly elevates in the luteal phase. HRV ratio shifts across cycle phases, reflecting changes in autonomic nervous system balance. Skin perfusion, measured via pulse wave velocity, decreases following the fertile window’s closing.

The 2019 Goodale et al. study in the Journal of Medical Internet Research was a prospective longitudinal study with 237 Swiss women who wore the Ava bracelet nightly for up to a year. Ovulation was confirmed using urinary LH tests. Using cross-classified mixed-effects models, the researchers demonstrated statistically significant phase-based shifts in skin temperature, heart rate, and respiratory rate (all P less than 0.001). HRV and skin perfusion also varied across cycle phases (P less than 0.05). The machine learning algorithm trained on these concurrent signals achieved 90% fertile window detection accuracy.

A 2022 study by Yu et al. in Reproductive Biology and Endocrinology provided complementary evidence, showing that combining BBT with heart rate data improved fertile window prediction to 87.46% accuracy among regular menstruators (AUC 0.8993). However, for irregular menstruators, accuracy dropped to 72.51%, highlighting an ongoing challenge for wearable fertility prediction.

A 2024 narrative review by Cromack and Walter in the American Journal of Obstetrics and Gynecology surveyed 23 consumer fertility wearables and noted that while the market is expanding rapidly, clinical validation research remains limited across most devices. Ava’s published clinical study represents one of the most robust validations in the consumer fertility wearable category.

That is the science. Here is how the Ava Fertility Bracelet applies it.

What the Ava Fertility Bracelet Does Well

Ava’s five-sensor multi-parameter approach is its defining scientific advantage. By combining temperature, pulse rate, breathing rate, HRV, and perfusion data, the algorithm captures a broader physiological signature of the fertile window than any single-parameter device. This is not incremental. The difference between detecting one physiological signal and five concurrent signals is the difference between reading a single word and reading a sentence. The published 90% fertile window accuracy reflects this multi-dimensional approach.

The prospective identification of fertile days, rather than retrospective confirmation of ovulation, is practically critical for conception timing. Ava identifies an average of 5.3 fertile days per cycle according to the company, giving couples a wider window for timed intercourse compared to methods that confirm ovulation only after it has passed. For couples actively trying to conceive, this forward-looking capability directly addresses the most actionable question: when should we try?

The sleep-only wear model minimizes behavioral burden. Users put on the bracelet at bedtime and sync it in the morning. There are no mid-day measurements, no timed checks, and no behavioral discipline requirements beyond consistent nighttime wear. This passive data collection reduces the fatigue and frustration that causes many women to abandon daily BBT charting.

FDA clearance for fertility tracking, rather than general wellness classification, provides a regulatory credibility layer. This clearance means Ava has met FDA standards for its specific fertility-related claims, a threshold most competing wearables have not crossed.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Pricing, Access, and Practical Realities

Ava Fertility Bracelet retails at approximately $299 with no subscription required for core fertility tracking features. The companion app is free and provides daily fertility status, cycle history, upcoming fertile window projections, and pregnancy mode. Some premium analytics features may be offered as optional upgrades, but the fundamental fertile window detection functionality is included with the hardware purchase.

Total first-year cost of ownership is $299. The device is rechargeable via USB and designed for approximately one year of nightly use before battery degradation may require replacement. The sealed battery is not user-replaceable, meaning the device itself may need replacement after 12 to 18 months of use, creating a potential recurring hardware cost for long-term users.

Ava is FDA cleared for fertility tracking and is confirmed HSA and FSA eligible. The FDA clearance specifically covers fertility awareness claims; Ava is not cleared as a contraceptive device. Women using Ava for natural family planning or contraceptive purposes should understand this regulatory distinction.

Availability note: Ava has undergone corporate changes since its initial launch, and product availability may vary by market. Users should verify current availability and warranty terms before purchasing, as the consumer fertility wearable market has seen companies enter and exit the space.

Who the Ava Fertility Bracelet Is Best For

Ava is purpose-built for women actively trying to conceive who want the most scientifically validated wearable approach to fertile window detection. Couples who have been trying to conceive for several months without success and want to optimize timing without immediately pursuing clinical fertility workups represent the core audience. Women who find daily BBT charting or frequent LH test strips burdensome will appreciate the passive, sleep-only data collection model.

Women with regular menstrual cycles (24 to 35 days) will get the best results from Ava’s algorithm, which is trained primarily on data from regular menstruators. The 2019 clinical study was conducted with conception-seeking women, and the algorithm’s performance may be optimized for this use case.

Women with highly irregular cycles should set realistic expectations. The published research shows significantly reduced accuracy for irregular menstruators. Women who need contraceptive-grade fertility awareness should consider Natural Cycles, which holds FDA De Novo clearance specifically for contraceptive use. Users who want a multi-function health wearable (fitness, sleep, heart rate tracking throughout the day) will find Ava limited, as it is designed exclusively for nighttime fertility monitoring and does not function as a daytime health tracker.

How the Ava Fertility Bracelet Compares

Tempdrop 2.0 ($149 to $199) measures continuous skin temperature during sleep via an armband and uses a single-parameter algorithm to determine BBT. Tempdrop is significantly less expensive, requires no subscription, and is well-suited for users who practice traditional sympto-thermal methods and want better BBT data. However, Tempdrop measures only temperature, while Ava tracks five parameters simultaneously. The 90% fertile window accuracy demonstrated in Ava’s published clinical trial has not been matched by published data from single-parameter BBT devices.

The Oura Ring Gen 4 ($349 to $499 plus $5.99/month subscription) provides cycle insights based on skin temperature and heart rate, among other metrics. Oura reports a temperature deviation from personal baseline rather than absolute BBT, and its cycle features are positioned as general wellness insights rather than FDA-cleared fertility claims. Oura functions as a comprehensive health tracker with cycle features added; Ava is a purpose-built fertility device.

Natural Cycles ($99.99/year plus thermometer) is the only FDA-cleared digital contraceptive and uses oral BBT with an algorithm. It requires daily morning measurement discipline but costs substantially less than Ava over a multi-year timeframe. For users whose primary goal is contraception rather than conception, Natural Cycles’ regulatory clearance for contraceptive use makes it the appropriate choice.

Clearblue Advanced Digital OPK ($39.99 to $49.99 per kit) detects LH and estrogen surges in urine, identifying up to four fertile days. This biochemical approach measures hormones directly rather than inferring hormonal status from physiological proxies. Clearblue is significantly cheaper per cycle but requires daily urine testing during the relevant window.

Limitations and Open Questions

Ava’s published clinical validation, while strong relative to competing wearables, was conducted by the company’s own research team (Goodale et al. were Ava AG employees or affiliates). Independent, third-party validation of the 90% fertile window accuracy claim would strengthen confidence in the device’s performance. The research was also conducted exclusively with conception-seeking women, and performance in other populations (women tracking for health awareness, perimenopause monitoring) has not been separately validated.

The algorithm’s performance for irregular menstruators remains a significant limitation. The broader literature on wearable fertility prediction consistently shows reduced accuracy for women with irregular cycles, and Ava has not published data specifically addressing this population.

The sealed battery and approximately 12 to 18 month device lifespan create a recurring hardware cost that may exceed the initial purchase price over a multi-year fertility journey. For couples who attempt conception over two to three years, total device costs could reach $600 to $900.

Corporate stability is a relevant consideration. The consumer fertility wearable market has seen company closures, pivots, and product discontinuations. Users should evaluate current company status, warranty terms, and long-term app support commitments before investing.

What This Means for Your Health

Reproductive health is health. Understanding your cycle is not a niche interest; it is a window into systemic physiology. The hormonal cascade that drives the menstrual cycle affects cardiovascular function, bone density, metabolic health, mood, sleep quality, and cognitive performance. Disruptions in cycle regularity can signal thyroid dysfunction, polycystic ovary syndrome, hypothalamic amenorrhea, or early perimenopause. A device that continuously monitors five physiological parameters across the cycle provides data that extends well beyond conception timing.

Within Healthcare Discovery‘s Five Pillars framework, fertility tracking intersects with sleep (overnight physiological data reflects sleep quality and circadian alignment), movement (exercise intensity affects cycle regularity and hormonal balance), nutrition (metabolic health directly influences reproductive hormone production), and mindset (understanding your cycle reduces the anxiety and unpredictability of reproductive health management).

The broader longevity context is that reproductive health is a leading indicator of overall physiological resilience. Women with regular, healthy menstrual cycles are, on average, demonstrating that their hypothalamic-pituitary-ovarian axis is functioning well, which reflects broader neuroendocrine health. Monitoring this system with the precision that Ava provides is a form of health intelligence that serves women whether they are trying to conceive, tracking for awareness, or simply paying closer attention to the signals their body produces every month.

The Ava Fertility Bracelet represents the most clinically validated multi-parameter wearable approach to fertile window detection currently available to consumers. Its science is published, its regulatory clearance is genuine, and its passive overnight monitoring model solves the compliance challenge that has limited BBT charting for decades. For women actively trying to conceive, the question is whether the published 90% accuracy and the multi-parameter advantage justify the $299 investment. For many, the answer is straightforward.

Frequently Asked Questions

Is the Ava Fertility Bracelet FDA cleared?
Yes. Ava holds FDA clearance specifically for fertility tracking. This means the device has met FDA standards for its fertility-related claims, including fertile window identification. This clearance distinguishes Ava from general wellness wearables that cannot make specific fertility claims. Note that Ava is cleared for fertility tracking, not for contraceptive use.

How accurate is Ava at detecting the fertile window?
A 2019 prospective longitudinal study published in the Journal of Medical Internet Research, involving 237 women, found that Ava’s multi-parameter algorithm detected the fertile window with 90% accuracy (95% CI 0.89 to 0.92). This remains one of the strongest published clinical validations for any consumer fertility wearable. The study tracked regular menstruators; accuracy for women with irregular cycles has not been separately published.

Does Ava require a subscription?
No. The $299 purchase price includes full access to the companion app’s core fertility features: daily fertility status, cycle history, fertile window projections, and pregnancy mode. Some optional premium analytics may be available as upgrades, but the fundamental fertile window detection functionality is subscription-free.

How many fertile days does Ava detect per cycle?
Ava identifies an average of 5.3 fertile days per cycle according to the company’s published data, which aligns with the biological fertile window of approximately six days (five days before ovulation plus the day of ovulation). This prospective identification of multiple fertile days provides a wider timing window for conception compared to retrospective BBT methods.

Can Ava be used as a contraceptive?
No. Ava is FDA cleared for fertility tracking and conception timing, not for contraception. Women seeking a wearable or app-based contraceptive should consider Natural Cycles, which is the only digital fertility product with FDA De Novo clearance specifically for contraceptive use, with a reported 93% typical use effectiveness rate.

Is the Ava Bracelet HSA or FSA eligible?
Yes. The Ava Fertility Bracelet is confirmed eligible for purchase using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds, which can reduce the effective out-of-pocket cost for users with qualifying health plans.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.